Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Buja, Paolo (2008) Stent medicati e rivascolarizzazione del tronco comune coronarico. [Tesi di dottorato]

Full text disponibile come:

[img]
Anteprima
Documento PDF
2853Kb

Abstract (inglese)

AIMS. Although the revascularization of left main coronary artery disease is surgical, the percutaneous treatment with drug-eluting stents seems to be safe and feasible. We reported our clinical experience in this context, adopting a provisional stenting strategy and comparing these therapeutical options.
MATERIAL AND METHODS. Between November 2003 and September 2007, all patients with symptomatic left main disease were evaluated for drug-eluting stent implantation. Unprotected procedures were considered if a suitable anatomy was associated to contraindication to surgery or patient preference; all cases were discussed with the surgeon. Myocardial infarctions presenting with ST-elevation were excluded. A provisional stenting strategy was adopted in case of bifurcation involvement.
According to the type of percutaneous procedure, patients were divided in protected left main group (PLM) and in unprotected left main one (UPLM); as comparison, we selected a matched cohort from the surgical database who received a coronary artery by-pass graft (CABG). Follow-up was clinical and included the occurrence of major adverse events (MAE), i.e. cardiac death, myocardial infarction, stent thrombosis, major bleedings, major periprocedural complications and target vessel revascularizations; moreover, we observed the total mortality rate.
RESULTS. Sixty-nine patients were enrolled: 19 in the PLM group, 25 in the UPLM one and 25 in the CABG one; the distal bifurcation was involved in more than 85% of them and the side branch needed for stent implantation in 15.9% of patients. Angiographic success was achieved in all cases; only the CABG group had in-hospital MAE (16%, p<0.01) with the longer hospital stay (PLM 3.9, UPLM 4.1, CABG 8.4, days, mean, p=0.059). At a median time of 24.1 months, the CABG group had more MAE than the other ones (PLM 21.1%, UPLM 24%, CABG 28%, p ns): no stent thrombosis occurred, but 4 patients had a non ST-elevation myocardial infarction (PLM 10.5%, UPLM 4%, CABG 4.2%, p ns). The total rate of target vessel revascularizations was 21.1% in the PLM group, 24% in the UPLM one and 16% in the CABG one (p ns): a new percutaneous intervention was performed in most of them (69.2%). The total mortality was superior in the UPLM group (PLM 5.3%, UPLM 12%, CABG 8%, p ns) but the only cardiac death occurred during the perioperative phase of a surgical patient.
CONCLUSIONS. Our experience suggests that a provisional stenting strategy with drug-eluting stents for selected patients with left main coronary disease appears to be safe and effective with a low need for side branch stenting. Clinical results are good also in case of unprotected procedures and at follow-up. Surgical revascularization seems to have an higher rate of in-hospital complications with a lower rate of target vessel revascularizations, compared to percutaneous treatment.


Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Razzolini, Renato
Dottorato (corsi e scuole):Ciclo 19 > Corsi per il 19simo ciclo > SCIENZE CARDIOVASCOLARI
Data di deposito della tesi:Gennaio 2008
Anno di Pubblicazione:Gennaio 2008
Parole chiave (italiano / inglese):tronco comune stent medicato coronarico
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/11 Malattie dell'apparato cardiovascolare
Struttura di riferimento:Dipartimenti > Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari
Codice ID:466
Depositato il:18 Set 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

[1] Kern MJ. Coronary blood flow and myocardial ischemia. In: Braunwald's heart disease: a textbook of cardiovascular medicine. Part VI: Atherosclerotic cardiovascular disease; Zipes DP, Libby P, Bonow RO, Braunwald E, editors. 7th edition 2005, Elsevier Saunders, Philadeliphia, Pennsylvannia, USA. Cerca con Google

[2] Cutlip D, Chauhan M, Baim D, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol, 2002; 40 (12): 2082-2089. Cerca con Google

[3] Popma JJ, Tulli M. Drug-eluting stents. Cardiol Clin, 2006; 24: 217-231. Cerca con Google

[4] Silber S, Albertsson P, Aviles SS, et al. The task force for percutaneous coronary interventions of the European Society of Cardiology: Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26: 804-847. Cerca con Google

[5] Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2005; 113: 156-175. Cerca con Google

[6] Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main, Circulation, 2005; 111: 791-795. Cerca con Google

[7] Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol, 2005. 45 (3): 351-356. Cerca con Google

[8] Arampatzis CA, Lemos PA, Tanabe K, et al. Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol, 2003; 92: 327-329. Cerca con Google

[9] Arampatzis CA, Lemos PA, Hoye A, et al. Elective sirolimuseluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome. Catheter Cardiovasc Interv, 2004; 62: 292-296. Cerca con Google

[10] de Lezos JS, Medina A, Pan M, et al. Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J, 2004. 148 (3): 481-485. Cerca con Google

[11] Buszman P. LEMANS. A porspective, randomized trial of stent implantation vs by-pass graft surgery in patients with left main coronary artery disease. TCT 2005; October 16-21, 2005; Washington, DC, USA. Cerca con Google

[12] Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2006; 47: 864-70. Cerca con Google

[13] Valgimigli M, Malagutti P, Aoki J, et al. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease. A combined RESEARCH and T-SEARCH long-term analysis. J Am Coll Cardiol 2006; 47: 507-514. Cerca con Google

[14] Takagi T, Stankovic G, Finci L, et al. Results and lon-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation, 2002; 106: 698-702. Cerca con Google

[15] Tan WA, Tamai H, Park SJ, et al, for the ULTIMA Investigators. Long-term clinical outcomes after unprotected left main trunk revascularization in 279 patients. Circulation 2001; 104: 1609-1614. Cerca con Google

[16] Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005; 293: 2126-2130. Cerca con Google

[17] Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol, 2005; 46: 1446-1455. Cerca con Google

[18] Colombo A. Bifurcation lesions. Ital Heart J, 2005. 6 (6): 475-488. Cerca con Google

[19] Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technic and a preliminary report of its application. Circulation 1964; 30: 654-670. Cerca con Google

[20] Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-68. Cerca con Google

[21] Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable intraluminal graft: a preliminary study: work in progress. Radiology 1985; 156: 73-77. Cerca con Google

[22] Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. Circulation 1987; 76: 450-457. Cerca con Google

[23] Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-706. Cerca con Google

[24] Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: 916-927. Cerca con Google

[25] Altmann DB, Racz M, Battleman DS, et al. Reduction in angioplasty complications after theintroduction of coronary stents: results from a consecutive series of 2242 patients. Am Heart J 1996; 132: 503-507. Cerca con Google

[26] Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495. Cerca con Google

[27] Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501. Cerca con Google

[28] Ulrich MR, Brock DM, Ziskind AA. Analysis of trends in coronary artery bypass grafting and percutaneous coronary intervention rates in Washington State from 1987 to 200. Am J Cardiol, 2003; 92: 836-839. Cerca con Google

[29] Indolfi C. Attività  dei Laboratori Italiani di Emodinamica e Cardiologia Interventistica nel 2002. Emodinamica, 2003; Suppl. 35: 2-5. Cerca con Google

[30] Daemen J, Serruys P. Drug eluting stent update 2007. Part I: a survey of current and future generation drug-eluting stents: meaningful advances or more of the same?. Circulation, 2007; 116: 316-328. Cerca con Google

[31] Daemen J, Serruys P. Drug eluting stent update 2007. Part II: unsettled issues. Circulation, 2007; 116: 961-968. Cerca con Google

[32] Curfman GD. Sirolimus-eluting stents. N Engl J Med, 2002; 346 (23): 1770-1771. Cerca con Google

[33] Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Eng J Med, 1995; 331 (15): 1004-1015. Cerca con Google

[34] Kimura T, Abe K, Shizuta S, et al. Long-term clinical and angiographic follow-up after coronary stentn placement in native coronary arteries. Circulation, 2002; 105: 2986-2991. Cerca con Google

[35] Bennett MR. In-stent stenosis: pathology and implications for the develpoment of drug eluting stents. Heart, 2003; 89: 218-224. Cerca con Google

[36] Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol, 1999; 10: 499-506. Cerca con Google

[37] Welt FGP, Rogers C. Inflammation and restenosis in the stent era. Aterioscler Thromb Vasc Biol, 2002; 22: 1769-1776. Cerca con Google

[38] Ribichini F. In-stent restenosis. Ital Heart J, 2001; 2: 728-735. Cerca con Google

[39] Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N Engl J Med, 2006; 354 (5): 483-495. Cerca con Google

[40] Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med, 2007; 356: 998-1008. Cerca con Google

[41] Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006; 48: 193-202. Cerca con Google

[42] Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus eluting stents: angioscopic findings. J Am Coll Cardiol, 2006; 47: 2108-2111. Cerca con Google

[43] Castagna MT, Mintz GS, Leiboff BO, et al. The contribution of "mechanical" problems to in-stent restenosis: an intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J, 2001; 142: 970-974. Cerca con Google

[44] Takebayashi H, Kobayashi Y, Mintz GS, etal. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. Am J Cardiol, 2005; 95: 498-502. Cerca con Google

[45] Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation, 2006; 113: 2293-2300. Cerca con Google

[46] Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J, 2006; 27: 166-170. Cerca con Google

[47] Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000; 101: 1899-1906. Cerca con Google

[48] Finn AV, Nakazawa G, Joner M, et al. Vascular response to drug-eluting stents. Importance of delayed healing. Arterioscler Thromb Vasc Biol, 2007; 27: 1500-1510. Cerca con Google

[49] Meier P, Zbinden R, Togni M, et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol, 2007; 49: 15-20. Cerca con Google

[50] Holmes DR Jr, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents. An objective appraisal. J Am Coll Cardiol, 2007; 50: 109-118. Cerca con Google

[51] Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation, 2001; 103: 1967-1971. Cerca con Google

[52] Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007; 115: 2344-2351. Cerca con Google

[53] Kereiakes DJ, Choo JK, Young JJ, Broderick, TM. Thrombosis and drug eluting stents: a critical appraisal. Rev Cardiovasc Med, 2004; 5: 9-15. Cerca con Google

[54] Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol, 2005; 45: 456-459. Cerca con Google

[55] Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation, 1996; 94: 1519-1527. Cerca con Google

[56] Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol, 2002; 40: 1567-1572. Cerca con Google

[57] Moussa I, Mario CD, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors, and clinical outcome. J Am Coll Cardiol, 1997; 29: 6-12. Cerca con Google

[58] Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med, 2007; 356: 1020-1029. Cerca con Google

[59] U.S. Food and Drug Administration. Circulatory System Devices Panel meeting. December 7— 8, 2006. www.fda.gov. February 7, 2007. Vai! Cerca con Google

[60] Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007; 356: 1030-1039. Cerca con Google

[61] Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007; 356: 989-997. Cerca con Google

[62] Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009 -1019. Cerca con Google

[63] Curfman GD, Morrissey S, Jarcho JA, et al. Drug-eluting coronary stents—promise and uncertainty. N Engl J Med, 2007; 356: 1059-1060. Cerca con Google

[64] Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol, 2005; 45: 947-953. Cerca con Google

[65] Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol, 2005; 45: 2088-2092. Cerca con Google

[66] Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents. Evolving concepts and perspectives. J AM Coll Cardiol, 2007; 50: 119-127. Cerca con Google

[67] Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. J Am Coll Cardiol, 2007; 49: 734-739. Cerca con Google

[68] Eikelboom JW, Hirsh J. Bleeding and management of bleeding. Eur Heart J, 2006; 8 Suppl: G38-G45. Cerca con Google

[69] Kaul S, Shah PK, Diamond GA. As time goes by. Current status and future directions in the controversy over stenting. J Am Coll Cardiol, 2007; 50: 128-137. Cerca con Google

[70] Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA, 2007; 297: 1992-2000. Cerca con Google

[71] Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA, 2007; 297: 2001-2009. Cerca con Google

[72] Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 2007; 370: 937-948. Cerca con Google

[73] Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med, 2007; 355: 1949-1952. Cerca con Google

[74] Lenzen MJ, Boersma E, Bertrand ME, et al. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J, 2005; 26: 1169-1179 Cerca con Google

[75] Taylor HA, Deumite NJ, Chaitman BR, Davis KB, Killip T, Rogers WJ. Asymtpomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. Circulation, 1989; 79: 1171-1179. Cerca con Google

[76] Caracciolo EA, Davis KB, Sopko G, et al for the CASS Investigators. Comparison of surgical and medical group survival in patients with left main coronary artery disease: long-term CASS experience. Circulation, 1995; 91: 2325-2334 Cerca con Google

[77] Chaitman BR, Fisher LD, Bourassa MG, et al. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). Am J Cardiol, 1981; 48: 765-777. Cerca con Google

[78] Ellis SG,Hill CM, Lytle BW. Spectrum of surgical risk for left main coronary stenoses: benchmark for potentially competing percutaneous therapy. Am Heart J, 1998; 135: 335-338. Cerca con Google

[79] Newman MF, Kirchner JL, Phillips-Bute B, et al. Neurological outcome research group and the cardiothoracic anesthesiology research endeavors investigators. N Engl J Med, 2001; 344: 395-402. Cerca con Google

[80] O'Keefe JH Jr, Hartzler GO, Rutherford BD, et al. Left main coronary angioplasty: early and late results of 127 acute and elective procedures. Am J Cardiol, 1989: 64: 144-147. Cerca con Google

[81] Black A, Cortina R, Bossi I, et al. Unprotected left main coronary artery stenting: correlates of midterm survival and impact of patient selection. J Am Coll Cardiol, 2000; 35: 1543-1550. Cerca con Google

[82] Silvestri M, Barragan P, Sainsous J, et al. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol, 2000; 35: 1543-1550. Cerca con Google

[83] Wong P, Wong V, Tse KK, et al. A prospective study of elective stenting in unprotected left main artery disease. Catheter Cardiovasc Interv, 1999: 46: 153-159. Cerca con Google

[84] Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). Am J Cardiol, 2006; 98: 54-59. Cerca con Google

[85] Sheiban I, Meliga E, Moretti C, et al. Long-term clinical and angiographic outcomes of treatment of unprotected left main coronary artery stenosis with sirolimus-eluting stents. Am J Cardiol, 2007: 100: 431-435. Cerca con Google

[86] Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation, 2006; 113: 2541-2547. Cerca con Google

[87] Valgimigli M, Malagutti P, Rodriguez-Granillo GA, et al. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries. J Am Coll Cardiol. 2006; 47:1530-1537. Cerca con Google

[88] Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of sirolimus-eluting stent for unprotected left main coronary artey revascularization. J Am Coll Cardiol, 2006; 47: 871-877. Cerca con Google

[89] Chieffo A, Park SJ, Valgimigli M, et al. Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery a multicenter registry. Circulation, 2007; 116: 158-162. Cerca con Google

[90] Al Suwaidi J, Berger PB, Rihal CS, et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol, 2000; 35: 929-936. Cerca con Google

[91] Yamashita T, Nishida T, Adamian MG, et al. Bifurcation lesions: two stents versus one stent - immediate and follow-up results. J Am Coll Cardiol, 2000; 35: 1145-1451. Cerca con Google

[92] Lefèvre T, Louvard Y, Morice MC, et al. Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv, 2000; 49: 274-283. Cerca con Google

[93] Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004; 109: 1244-1249. Cerca con Google

[94] Lefèvre T, Ormiston J, Guagliumi G, et al. The FRONTIER Stent Registry. Safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions. J Am Coll Cardiol 2005; 46: 592-8. Cerca con Google

[95] Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamoi R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothoracic Surg, 1999; 16: 9-13. Cerca con Google

[96] Colombo A, Chieffo A. Drug-eluting stent update 2007. Part III: technique and unapproved/unsetteled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and mutlivessel disease. Circulation, 2007: 116: 1424-1432. Cerca con Google

[97] Pan M, de Lezo JS, Medina A, et al. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus a complex srtategy. Am Heart J, 2004; 148: 857-64. Cerca con Google

[98] Steigen TK, Maeng M, Wiseth R, et al; for the Nordic PCI Study Group. R andomized study on simple versus a complex stenting of coronary artery bifurcation lesions: the Nordic Bifurcation Study. Circulation, 2006; 114: 1955-1961. Cerca con Google

[99] Gersh BJ, Frye RL. Methods of coronary revascularization - things may not be as they seem. N Engl J Med, 2005; 352: 2235-2237. Cerca con Google

[100] Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation, 2003; 108: 1701-1706. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record